GODAVARI-BIOREFINERIES
10.6.2024 13:11:26 CEST | Business Wire | Press release
A new specialty biochemical plant has been inaugurated at the Sakarwadi manufacturing facility in Maharashtra, India where Godavari Biorefineries Limited (GBL) intends to produce biobased chemicals to support the green and net-zero ambitions of its clientele in different markets across the globe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240607431453/en/
Inauguration of new specialty biochemical plant at the Sakarwadi manufacturing facility in Maharashtra, India (Photo: Business Wire)
GBL has taken a next step with the intention to support the world’s ambition for net-zero strategies by developing a multi-purpose plant which aims to produce biobased chemicals for coatings & resins, cosmetics, pharmaceuticals and food & fragrances markets.
“At GBL we make Specialty Chemicals from Renewable Resources using Green Chemistry. We work with farmers to develop sustainable agricultural value chains that serve as a feedstock for our biobased chemicals,” said Samir Somaiya, Chairman of Somaiya Group and Godavari Biorefineries Ltd.
This multi-purpose plant is one of the steps GBL has taken to support and partner with leading companies to enlarge the amount of biobased chemical blocks in the chemical industry for different markets and products, and intends to produce biochemicals like biobutanol, biobased ethers and esters in this plant. GBL has the strategy to further develop and scale-up its capacity in the coming years in volumes and for new biobased chemicals.
“We work in close relation and collaboration with our customers to develop and produce new biobased chemical building blocks in several markets. In co-creation we work from R&D to pilot scale towards the (semi-)commercial scale of new biobased chemicals into several applications and products that can become biobased and green. It is a journey towards net-zero where we are open for new partnerships and new insights, and define pathways to take together,” said Sangeeta Srivastava, CEO of Godavari Biorefineries Ltd.
GBL is a flagship company of the diversified Somaiya group with an experience of over eight decades in the sugar industry and over six decades in the biobased chemicals industry. We work with our farmers in sugarcane and other biomass crops to create value for their communities and our customers' value chains.
Padma Vibhushan Prof. M. M. Sharma, a luminary in the field of chemical engineering, performed the ribbon-cutting ceremony and delivered an inspiring address. He highlighted the critical role of R&D in the chemical industry and complimented GBL efforts in establishing a plant that represents the future of specialty chemicals manufacturing.
For information please visit: http://godavaribiorefineries.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240607431453/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Only AI Crypto Lead Prioritization Solution Built With Law Enforcement, for Law Enforcement: Elliptic Launches Pulse24.9.2026 15:15:00 CEST | Press release
Pulse delivers actionable leads in seconds, no crypto expertise required, enabling decisions in the field Elliptic, the global leader in on-chain risk, today launched Pulse. Pulse puts crypto lead prioritization directly in the hands of every frontline law enforcement and government officer. Crypto now touches every part of law enforcement, from the patrol officer on the street to the detective assigned to investigate the case. Pulse gives each of them a quick, accurate financial summary and a starting point: whether that's a crypto address on a suspect's phone, in a scam ATM victim's receipt, uncovered during a vehicle or pocket search, or found at the scene of an overdose, an arrest, or a seizure. An officer can input anything that looks like a wallet address or transaction hash. Pulse identifies it, reasons over the result, and returns a summary in plain language, enough for the officer to decide on the spot whether the case needs escalation. If a case needs further investigation, o
Just 4.7% of Financial Institutions Continuously Update Their Compliance Monitoring and Controls as Risk Changes, New Research Finds24.9.2026 15:04:00 CEST | Press release
As financial crime threats, regulations and transaction volumes evolve dynamically, most compliance programs remain built around periodic review SymphonyAI, a global leader in vertical AI product platforms, and AML Intelligence, the leading source of news and insight for the financial crime compliance community, today released the FinCrime Frontier 2026–27 Report, finding that most financial institutions still rely on periodic review cycles to manage financial crime risk, even as the threats and regulations they are meant to track continue to evolve dynamically. Based on the perspectives of more than 200 financial crime and compliance leaders, including senior leaders from major global financial institutions, the research finds that just 4.7% of financial institutions continuously update their compliance monitoring and controls as risk changes, while 56.8% have not adopted always-on compliance monitoring at all, are only exploring it, or remain at an early, pilot-stage level. The findi
SymphonyAI Introduces Symphony Risk Intelligence, an Agent-native Platform That Unlocks Always-on Compliance™ — the Catalyst for Transforming the Financial Crime Operating Model24.9.2026 15:04:00 CEST | Press release
New industry research finds just 4.7% of financial institutions continuously update their compliance monitoring and controls as risk changes, a gap regulators are now pushing institutions to close SymphonyAI today introduced Symphony Risk Intelligence (SRI), an enterprise-grade, agent-native platform built to unlock Always-on Compliance™. This is a critical shift from periodic to continuous risk and compliance management, in which institutions continuously reassess risk and adapt controls as regulations, threats and business activity change, rather than waiting for the next scheduled review. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260924914614/en/ Current approaches have reached their structural limits. The FinCrime Frontier 2026–27 Report, released recently by SymphonyAI and AML Intelligence, finds just 4.7% of financial institutions continuously update their compliance monitoring and controls as risk changes, and 76
Boomi Appoints Mike Hickman as Chief Financial Officer24.9.2026 15:00:00 CEST | Press release
Three-decade technology finance leader joins Boomi to scale global operations, bringing experience across IPO, take-private, and large-scale acquisition integration Boomi, the data activation company for AI, today announced the appointment of Mike Hickman as Chief Financial Officer. Hickman will lead Boomi's global finance and accounting organization, spanning financial planning and analysis, accounting, treasury, tax, and financial reporting. He reports to Boomi Chairman and Chief Executive Officer Steve Lucas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260924761566/en/ Boomi Appoints Mike Hickman as Chief Financial Officer Hickman brings three decades of senior finance leadership in high-growth SaaS and technology companies, with experience across the full corporate lifecycle: scaling through IPO, executing a take-private, and integrating large acquisitions. He joins from Proofpoint, where he spent seven and a half yea
Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 14:40:00 CEST | Press release
Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom